In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

A recent survey found only half of Americans think so. On a Monday morning edition of FOX45 Morning News Shannon Lilly spoke with shock trauma critical care surgeon Dr. Mira Ghneim about 'Stop the ...

US President Donald Trump watched translated excerpts of an interview given by captivity survivor Eli Sharabi to the "Uvda" program, and invited him and other captivity survivors to the White ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

Eli Lilly plans a $27 billion investment to establish four manufacturing plants in the U.S., anticipated to generate 3,000 jobs for skilled workers and 10,000 construction jobs. The move aligns with ...